Skip to main content
NewslettersWatchlist

Replicel Life Sciences Inc(RP-X)
TSX Venture

Today's Change
Delayed Last Update

Replicel Life Sciences Inc

570 Granville Street
Suite 900
Vancouver BC V6C 3P1 CAN
P: 604-248-8730
F: 604-248-8690
https://www.replicel.com

Sectors & Indices

Sector
Industry
Employees

    Profile

    RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.

    Key Executives

    NameTitle
    David KwokCFO
    Rolf HoffmannChief Medical Officer
    Kevin McElweeChief Scientific Officer/Co-Founder
    Andrew SchutteCEO/Director/President
    Ben AustringCOO/Secretary
    David KwokCFO

    More from The Globe

    At midday: TSX struggles for direction as investors prepare for U.S. Fed decision
    Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 26.
    The close: Major North American indexes rise as megacap tech stocks rally
    A trader works on the floor at the New York Stock Exchange (NYSE) on April 25.
    Why this money manager is venturing back into emerging markets and adding more U.S. tech
    Illustration of Andrew Pyle for The Mover. Nov. 5, 2022. Illustration by Joel Kimmel
    How a Canadian pirate-clad pastor helped ignite Trump Media’s market frenzy
    Former President Donald Trump sits in Manhattan Criminal Court in New York, Thursday, April 25.
    Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders
    Dye & Durham Ltd. says it has launched a strategic review of its non-core assets in an effort to reduce its debt. The logo for Dye & Durham Ltd. is shown in this undated handout photo. THE CANADIAN PRESS/HO
    The close: U.S. stocks fall as GDP report spreads rate-cut gloom; Alphabet surges 15% in post market
    Traders work on the floor of the New York Stock Exchange shortly after the opening bell, Wednesday, April 24.
    Fiera Capital’s largest shareholder looks to sell stake in company
    Jean-Guy Desjardins, global CEO and founder of Fire Capital posses for a portrait at Fiera Capital, in Montreal on Monday, January 8, 2024. Evan Buhler/The Globe and Mail�
    The close: S&P 500 higher as markets weigh rising bond yields and upbeat U.S. earnings; TSX lower as rails slide
    The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.

    All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

    Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

    Financial data provided by Zacks Investment Research.